Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -35.76% | -39.32% | -47.58% | -53.18% | 47.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -35.76% | -39.32% | -47.58% | -53.18% | 47.99% |
| Cost of Revenue | 24.66% | 12.11% | -40.60% | -73.92% | -60.29% |
| Gross Profit | -45.81% | -25.39% | 31.38% | 82.37% | 68.39% |
| SG&A Expenses | 13.34% | -10.30% | -32.27% | -20.28% | -42.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.17% | 3.83% | -39.01% | -64.20% | -56.17% |
| Operating Income | -33.62% | -10.25% | 31.70% | 67.63% | 62.02% |
| Income Before Tax | -40.44% | 10.96% | -5,096.56% | 74.07% | 62.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.44% | 10.96% | -6,375.65% | 74.07% | 62.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.44% | 10.96% | -6,375.65% | 74.07% | 62.85% |
| EBIT | -33.62% | -10.25% | 31.70% | 67.63% | 62.02% |
| EBITDA | -33.84% | -11.06% | 31.48% | 67.77% | 62.01% |
| EPS Basic | 18.30% | 48.28% | -4,724.29% | 74.27% | 63.19% |
| Normalized Basic EPS | 24.95% | 39.26% | 55.79% | 75.59% | 65.59% |
| EPS Diluted | 18.30% | 48.28% | -4,216.17% | 74.27% | 63.19% |
| Normalized Diluted EPS | 24.95% | 39.26% | 55.79% | 75.59% | 65.59% |
| Average Basic Shares Outstanding | 71.94% | 72.20% | 34.49% | 0.81% | 0.93% |
| Average Diluted Shares Outstanding | 71.94% | 72.20% | 34.49% | 0.81% | 0.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |